Global Markets for Orphan Drugs

Published: July 23, 2021 |

BCC Research | 128 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

Highlights:

The global orphan drugs market should reach $248.2 billion by 2026 from $190.8 billion in 2021 at a compound annual growth rate (CAGR) of 5.4% for the forecast period of 2021 to 2026.

The biological orphan drugs segment of the global orphan drugs market is expected to grow from $141.8 billion in 2021 to $184.0 billion in 2026 at a CAGR of 5.3% for the forecast period of 2021 to 2026.

The non-biological orphan drugs segment of the global orphan drugs market is expected to grow from $48.9 billion in 2021 to $64.2 billion in 2026 at a CAGR of 5.6% for the forecast period of 2021 to 2026.

Report Scope:

The scope of this study includes orphan drugs used in the global pharmaceutical markets. This report analyzes the therapeutic applications of orphan drugs in rare and orphan diseases as well as examines the regulatory framework, patents, and recent innovations in the industry. The report also analyzes each submarket and its applications, projections and market shares. Technological issues include the latest trends and developments.

This report covers the U.S. and European markets, and emerging global markets such as India, Japan, China, Singapore, Taiwan, Korea, Canada, Brazil, Africa, Australia and New Zealand.

This report also analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases. The report examines the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources. In addition, this report provides an overview of the global orphan drugs market and its competitive landscape.

Report Includes:

26 tables
An updated review of the global markets for orphan drugs (ODs) within the healthcare industry
Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Estimation of market size and revenue forecast for biological and non-biological orphan drugs, and corresponding market share analysis by product type, therapeutic category and geographic region
Emphasis on the regulation of clinical trials on orphan designated drugs by leading regulatory authorities including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) of Japan
Review of the current status and trends in clinical trials for the development of drugs in rare diseases among the three registries from the U.S., EU and Japan
Discussion of successful orphan medicinal products, rising influence of pharmacogenomics in the ODs market, information on specific rare diseases for which orphan drugs exist
Assessment of the most promising therapeutic areas in the industry and leading orphan drugs in these areas
Highlights of the industry structure for orphan drugs, pricing and reimbursement policies, COVID-19 impact assessment and market share analysis of the top 20 manufacturers of orphan drugs
Descriptive company profiles of the market leading participants, including AbbVie Inc., Eli Lilly, Johnson & Johnson, Merck & Co., Pfizer Inc. and Sanofi-Aventis

Product Code: PHM038F

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
What's New in This Update
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Definitions and Background

Types of Orphan Drugs
Biological Orphan Drugs
Chemical or Non-biological Orphan Drugs
Global Definitions of Rare Diseases by Country/Region
U.S.
EU
Taiwan
Japan
Australia

Chapter 4 FDA Regulation of Clinical Trials in Orphan-Designated Drugs

Regulation of Drugs and Biologics
Accelerated Approvals
Fast-track Designation
Breakthrough Designation
Priority Review
Controlled Substances Act
Special Protocol Assessments
New Surveillance and Safety Requirements
Regulation of Clinical Trials in Orphan-Designated Drugs
Content and Format of a Sponsor's Request
Providing Written Recommendations
Refusal to Provide Written Recommendations
Orphan Drug Designation
Orphan Drug Exclusive Approval

Chapter 5 European Regulation of Clinical Trials in Orphan-Designated Drugs

European Orphan Regulation
Legal Framework
Applying for Orphan Designation
Application Challenges and Maintenance
Demonstrating Significant Benefit
Timelines
Activities After Orphan Designation: Annual Reports
Activities During Marketing Authorization Application
Maintenance of the Orphan Drug Status

Chapter 6 Asian Regulation of Clinical Trials in Orphan-Designated Drugs

Orphan Drug Designation System in Japan
Designation Criteria
Orphan Drug/Medical Device Designation Procedure
Designation Consultation
Regulation of Rare Diseases and Orphan Drugs in Taiwan
Regulation of Rare Diseases and Orphan Drugs in South Korea

Chapter 7 Trends in Clinical Trials for Drug Development in Rare Diseases

NCT, EUCTR and JPRN Registry Characteristics
The Relationship Among Clinical Trials, Diseases and Drugs
Characteristics of the Three Registries and Disease-Drug Relationships

Chapter 8 Global Orphan Drug Market Analysis

Market Overview
Market Revenue
Market Shares
Market by Region
Market Overview
Market Revenue
Market Share
Biological Orphan Drugs
Market by Region
Non-biological Orphan Drugs
Market by Region
Global Market by Product Type
Global Orphan Drug Sales by Therapeutic Category

Chapter 9 Industry Structure and Current Trends

Impact of COVID-19 on the Orphan Drug Market
Factors Boosting the Orphan Drug Market
Orphan Drug Act and Similar Legislation
Technological Advances and Genetic Codes
Generic Competition
Patent Expirations
Premium Pricing
Innovations in Manufacturing Technologies
Collaborations and Licensing Agreements
Challenges
Lack of Trained Professionals
Vulnerable Target Groups
Multiple Usages
Regulatory Challenge

Chapter 10 Orphan Drug Exclusivity and Pricing Policies

Reimbursed Price of ODs: Current Strategies and Potential Improvements
Comprehensive Value Assessment
Early Dialogues
Innovative Reimbursement Approaches
Societal Participation in Producing ODs

Chapter 11 Company Profiles

ABBVIE INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BRISTOL-MYERS SQUIBB
EISAI CO., LTD.
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO.
NOVARTIS AG
PFIZER INC.
SANOFI-AVENTIS
TAKEDA PHARMACEUTICAL CO., LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.

Chapter 12 Clinical Trials in Drugs for Rare Diseases

List of Clinical Trials in Drugs for Rare Diseases

Chapter 13 Appendix: References and Acronyms

References
Acronyms

List of Tables

Summary Table : Global Market for Orphan Drugs, by Product Type, Through 2026
Table 1 : Prevalence of Rare Diseases
Table 2 : Orphan-Designation Application Documents
Table 3 : Summary of Orphan Designation in Europe
Table 4 : Overview of Organizations and Responsibilities in Japan
Table 5 : Comparison of the Regulation of Rare Diseases and Orphan Drugs Worldwide
Table 6 : Characteristics of the NCT, EUCTR and JPRN Trials
Table 7 : Number of Trials in NCT, EUCTR and JPRN Trials, by Recruitment Status
Table 8 : Number of Trials in NCT, EUCTR and JPRN Trials, by Gender
Table 9 : Number of Trials in NCT, EUCTR and JPRN Trials, by Phase
Table 10 : Number of Trials in NCT, EUCTR and JPRN Trials, by Country
Table 11 : Top 20 Most Studied Rare Diseases, by Number of Trials
Table 12 : Top 20 Most Studied Rare Diseases, by Number of Diseases
Table 13 : Global Market for Orphan Drugs, by Product Type, Through 2026
Table 14 : Global Market for Orphan Drugs Share, by Product Type, 2020
Table 15 : Growth in Orphan Designations, by Region/Country, 2010-2020
Table 16 : Global Market for Orphan Drugs, by Region, Through 2026
Table 17 : Global Market Share of Orphan Drugs, by Region, 2020
Table 18 : Global Market for Biological Orphan Drugs, by Region, Through 2026
Table 19 : Global Market for Non-biological Orphan Drugs, by Region, Through 2026
Table 20 : Global Orphan Drug Sales, by Product Type, Through 2026
Table 21 : Global Orphan Drug Sales, by Therapeutic Category, Through 2026
Table 22 : Market Shares of Top 20 Companies, 2020
Table 23 : Orphan Drug Approvals and Exclusivity, 2020
Table 24 : Clinical Trials in Drugs for Rare Diseases
Table 25 : Acronyms Used in This report

List of Figures

Summary Figure : Global Market for Orphan Drugs, by Product Type, 2020-2026
Figure 1 : Orphan Designation Process, Japan
Figure 2 : Orphan Designation Consultation and Evaluation, Japan
Figure 3 : Comparison of the Three Registries (NCT, EUCTR, and JPRN), by Number of Trials
Figure 4 : Comparison of the Three Registries (NCT, EUCTR, and JPRN), by Number of Diseases
Figure 5 : Comparison of the Three Registries (NCT, EUCTR, and JPRN), by Number of Drugs
Figure 6 : Global Market Share of Orphan Drugs, by Product Type, 2020
Figure 7 : Global Market Share of Orphan Drugs, by Region, 2020
Figure 8 : Cumulative Change from Baseline in Total Market and Orphan Drug New Therapy Starts During COVID-19
Figure 9 : Conceptual Framework for Analyzing Current Strategies for Pricing Definition